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Antibodies against the Plasmodium falciparum P0 ribosomal phosphoprotein (PfP0) have been detected
exclusively but extensively in malaria-immune persons. Polyclonal rabbit and mice sera were raised against two
recombinant polypeptides of P. falciparum P0 protein, PfP0N and PfP0C, covering amino acids 17 to 61 and the
remaining amino acids 61 to 316, respectively. Sera against both these domains detected a 35-kDa protein from
Plasmodium yoelii subsp. yoelii, a rodent malarial parasite, and stained the surface of merozoites in immuno-
fluorescence assays. Total immunoglobulin G (IgG) purified from rabbit and mouse anti-PfP0 sera by ammo-
nium sulfate and DEAE-cellulose chromatography was used for passive transfer experiments in mice. Mice
passively immunized with both anti-PfP0N and anti-PfP0C showed distinctly lower levels of parasitemia than
control mice. With immunizations on days 21, 0, 1, 3, and 5, about 50% of both sets of mice receiving
anti-PfP0N and anti-PfP0C cleared the lethal 17XL strain of P. yoelii and revived by day 25. All the control mice
died by day 10. By extending the immunization schedule, the survival period of the mice could be extended for
every mouse that received anti-PfP0 IgG. These data demonstrate the cross-protection of the anti-PfP0 IgG and
establish parasite P0 protein as a target for invasion-blocking antibodies.
It has been documented that people living in areas of ma-
laria endemicity become immune to malaria after repeated
infections. Low levels of parasitemia in adults living in areas of
malaria endemicity often accompany this clinical immunity (2).
Passive transfer of gammaglobulins from such malaria-immune
adults into patients has resulted in clearance of parasites in
these patients (10, 12, 25, 29). These experiments worked
across geographic borders, as West African sera could cure
East African (12, 25) as well as Thai (29) malaria patients. It
has been proposed that the immunoglobulin G (IgG) subtype
(5) and monocytes (6) play important roles in such protection.
Pooled IgG from immune African donors, which could control
Plasmodium falciparum in Thai patients, was also able to con-
trol the parasite in Saimiri monkeys (6).
In order to elucidate the protective immunoglobulins and
their targets, a differential immunoscreening of an erythrocyte
stage-specific cDNA expression library of P. falciparum has
been performed earlier in our laboratory, using malaria-im-
mune and acute patient sera (22). This resulted in the identi-
fication of several novel cDNA clones, which reacted exclu-
sively and yet extensively with immune serum samples (22).
Clone lPf4, which reacted with the largest number of immune
sera (80 of 92), has been cloned and sequenced (15). This was
found to be the P. falciparum gene homologue of the ribosomal
phosphoprotein P0 (PfP0). Further characterization showed
that antibodies raised specifically to PfP0 inhibited the growth
of P. falciparum in vitro and reacted to the surface of mero-
zoites (8, 16).
Ribosomal phosphoprotein P0 is a neutral protein, related
to the family of the acidic ribosomal phosphoproteins P1 and
P2 because of the highly homologous carboxyl-terminal do-
main (26). There is evidence that P0 functions though the
formation of a (P1)2-P0-(P2)2 protein complex, which interacts
with the 28S large ribosomal subunit in eukaryotes (30, 34). A
role for the P proteins in the assembly of the GTPase binding
site in the large subunit of the ribosomes has been demon-
strated in rat tissue (35). Through gene disruption studies, it
has been documented that P0 protein is absolutely required for
cell viability in Saccharomyces cerevisiae (31). The P0 protein
has also been implicated in roles other than ribosomal, such as
an apurinic-apyramidinic endonuclease in the nuclei in Dro-
sophila melanogaster (36). It has also been shown to play a
regulatory role in Drosophila (14), and the level of P0 protein
is shown to be regulated during apoptosis and carcinogenesis
in mammalian cells (7, 21).
To test whether the IgG raised against PfP0 protein domains
has any effect on parasite growth in vivo, passive-transfer ex-
periments were performed in mice. In this paper we show that
mice passively immunized with IgG purified from sera raised in
rabbits and mice against the human malarial parasite P. falci-
parum P0 protein domains were protected against challenge
with the lethal 17XL variant of the rodent malarial parasite
Plasmodium yoelii. Normally protection at the asexual stages
has been documented to apply across a limited number of
strains, and certainly not across different plasmodial species
(11, 23, 28). This is the first instance of passive protection
documented across species of Plasmodium.
MATERIALS AND METHODS
Expression of domains of P0 as GST fusion proteins. A glutathione S-trans-
ferase (GST) reporter-based vector was used as an expression vector as described
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earlier (8, 16). The amino-terminal 45-amino-acid (a.a.) domain (a.a. 17 to 61)
and the 256-amino-acid carboxy-terminal region (a.a. 61 to 316) of PfP0 were
expressed as fusion proteins designated PfP0N and PfP0C, respectively. The
induction and lysis of the recombinant Escherichia coli cells containing the PfP0N
and PfP0C proteins were performed as described earlier (8). The cell lysates
were run on denaturing sodium dodecyl sulfate–10% polyacrylamide gel elec-
trophoresis (SDS-PAGE) and stained with Coomassie blue to check the fusion
proteins. Both fusion proteins were obtained as insoluble proteins.
Immunization of rabbits and mice with PfP0N and PfP0C domains. Immuni-
zations were carried out with fusion proteins eluted from the polyacrylamide gel,
as described earlier (8). Ten Swiss inbred mice were immunized intraperitoneally
with 50 mg of protein emulsified in Freund’s complete adjuvant. Booster doses
were given every 3 weeks with 15 mg of the protein preparation emulsified with
incomplete Freund’s adjuvant, and sera were collected every 2 weeks. To obtain
sera from rabbits, approximately 200 mg of PfP0N and PfP0C protein prepara-
tions was injected subcutaneously into two New Zealand White rabbits for each
protein, using standard protocols (18). Subsequent boosts were given with 100 mg
of protein at 3-week intervals, and sera were collected 2 weeks after each booster
dose. The rabbit and mouse sera were checked for specific antibody against the
fusion proteins by enzyme-linked immunosorbent assay (ELISA) and then
pooled for IgG purification.
ELISA. Wells of microtiter plates (Nunc, Roskilde, Denmark) were coated with 1
mg of the fusion protein in 200 ml of phosphate-buffered saline (PBS) overnight
at 4°C. Plates were then washed with PBS containing 0.05% Tween 20 (PBST)
and incubated with 400 ml of 5% milk in PBS for 1 h. After repeated washes with
PBST, plates were incubated with the dilutions of the different sera or IgG. The
binding of antibodies was detected by treatment with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG antibodies (Organon Teknika, Copen-
hagen, Denmark) and ABTS [2,29-azinobis(3-ethylbenzthiazolinesulfonic acid)].
The color was allowed to develop at room temperature, and the absorbance
values were read at 405 nm. To determine the titers of the sera, absorbance
values above the GST values were considered, with a cutoff at a reading of 0.10.
Western blotting and solution IFA. To prepare parasite protein for immuno-
blotting and merozoites for the immunofluorescence assay (IFA), mice infected
with P. yoelii strain 17XL were allowed to develop to about 50 to 60% para-
sitemia. Merozoites were prepared from infected blood which was incubated for
2 h at 37°C in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum
(2). The liberated merozoites were harvested at 4°C, washed, and resuspended in
complete RPMI 1640 medium at a concentration of 107 merozoites/ml. Intra-
cellular parasites were liberated from infected erythrocytes by saponin lysis (16).
The total intracellular parasite pellet and the merozoite pellet were solubilized
with 10 volumes of solubilization buffer (20 mM Tris-HCl [pH 7.8], 50 mM NaCl,
5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM phenylmeth-
ylsulfonyl fluoride, 1 mM iodoacetic acid, 0.1% sodium azide) at 4°C for 1 h. This
was then spun at 12,000 rpm for 20 min, and the supernatant containing the
solubilized protein suspension was used for Western blot analysis. The immu-
noblots were treated with the preimmune and anti-PfP0C sera after clearing off
the anti-GST antibodies by incubation with nitrocellulose filters coated with
lysates of E. coli cells expressing GST protein.
For the solution IFA (SIFA), merozoites were double-labeled with rabbit
anti-PfP0 antibodies and the monoclonal anti-MSP1 antibody Mab302 (23) for
30 min on ice. All the subsequent steps were also carried out on ice. Anti-PfP0
IgG (1 mg/ml) was diluted 1:50 in RPMI 1640 medium with 10% heat-inactivated
fetal bovine serum, while Mab302 culture medium was used directly. Merozoites
were washed three times with incomplete RPMI and resuspended at a 1:100
dilution of secondary antibody for 30 min. The secondary antibody solution
consisted of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
and rhodamine-conjugated goat anti-rabbit IgG (Boehringer, Mannheim, Ger-
many). Merozoites were washed and mounted under glass coverslips in 5 ml of
Citifluor mountant medium (Ted Pella Inc., Redding, Calif.) on glass slides. The
slides were observed under a Nikon microscope using a 3100 phase-contrast
objective.
IgG purification from polyclonal anti-PfP0 rabbit and mice sera. IgG was
prepared from 25 ml of pooled rabbit sera and 20 ml of mouse sera (pooled after
different bleeds), using standard protocols (18). After 50% ammonium sulfate
precipitation, the IgG was purified through a DEAE-cellulose column. The
fractions containing IgG were pooled and concentrated by lyophilization. The
IgG was run on SDS-PAGE to test for purity, and ELISAs were performed to
test the activity of the IgG against PfP0N and PfP0C proteins.
Passive-transfer experiments. The challenges were performed with the 17XL
variant of P. yoelii. Frozen stock parasites were injected into mice, and parasites
from the second round of passage (at about 10 to 15% parasitemia) were used for
the experiments. The parasite count used for challenge was determined by
enumerating the number of red blood cells on a hemocytometer and by estimat-
ing the percent parasitemia by microscopic examination of a thin slide smear
stained with Giemsa. For each of the passive-transfer experiments, parasites
were introduced on day 0, and parasitemia was monitored daily by preparing
slides from tail bleeds.
(i) Experiments I and II. The first two experiments were performed on sets of
six BALB/c mice for each treatment, with the injections of rabbit anti-PfP0N and
anti-PfP0C IgG given intraperitoneally. Specific preimmune sera obtained from
the same rabbits prior to immunizations with PfP0N and PfP0C were used as the
source of preimmune IgG P. yoelii 17XL parasites were used for the challenge
through the orbital route. For experiment I, 0.6 mg of IgG per mouse per day was
injected on days 21, 0, and 1, followed by 0.5 mg per mouse per day on days 3
and 5, and 104 parasites per mouse were used for challenge. For experiment II,
1 mg of IgG per mouse per day was introduced on days 21, 0, and 1, followed
by 0.5 mg per mouse per day on each day from days 2 to 7. In this experiment,
3 3 104 parasites were used for challenge.
(ii) Experiment III. Experiment III was performed with groups of six Swiss
inbred mice, with the intraperitoneal route for IgG and intravenous tail injec-
tions for the parasite. IgG purified from anti-PfP0N and anti-PfP0C mouse sera
were used in this experiment. One milligram of IgG per mouse per day was
injected on days 21, 0, and 1, followed by 0.5 mg of IgG per mouse per day on
days 4 and 5, and each mouse was challenged with 6 3 104 parasites of P. yoelii
17XL.
RESULTS
Detection of P. yoelii P0 with anti-PfP0 sera. To establish
that anti-PfP0 antibodies raised against P. falciparum P0 pro-
tein recognize the murine malarial parasite P0, Western blot
analysis was carried out. Figure 1 shows the reaction of protein
extracted from P. yoelii strain XL17 with rabbit anti-PfP0C
antibodies. All eukaryotic P0 proteins are approximately 35 to
38 kDa in size (15). A 35-kDa band was observed with mero-
zoites as well as asynchronous asexual-stage parasite extracts of
P. yoelii, while no reaction was observed with the preimmune
sera. The cross-reactivity was faint but distinct, with no other
protein bands reacting. This demonstrated the absence of any
other cross-reactive proteins of P. yoelii. The amount of P0
protein is higher in the intraerythrocytic stages than in mero-
zoites. P0 plays a role in protein synthesis, and trophozoites are
the stage where maximum protein synthesis occurs. We have
demonstrated earlier that the amount of P0 gene transcript is
greater during the trophozoite stages (18). Merozoites are
known to be a stage when no protein synthesis occurs (9), and
this may be a reason why the level of P0 is lower in merozoites.
The levels of P0 have recently been shown to be modulated in
mammalian cells (7, 21). The monoclonal Mab302 is known to
react to the carboxy-terminal domain of the MSP1 protein and
has been shown to immunoprecipitate 230-kDa along with 67-
FIG. 1. Western blot analysis of P. yoelii protein extract. Lane 1, 5 mg of
merozoite protein extract; lane 2, 10 mg of total asexual parasite extract. Samples
were run on SDS–10% PAGE under reducing conditions. Immunoblotting was
performed using preimmune sera (1:50 dilution) (A), rabbit anti-PfP0C sera
(1:50 dilution) (B), or anti-MSP1 monoclonal antibody Mab302 (ascites fluid
used at 1:100 dilution) (C). The arrowhead shows the 35-kDa P0 protein. Sizes
are shown on the left (in kilodaltons).
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and 36-kDa fragments of MSP1 protein (23). It interacts only
with the 67-kDa fragment in the merozoite stage on a dena-
turing gel.
The P0 ribosomal protein is expected to be an internal pro-
tein, with a role in ribosomal assembly. However, a surface
localization of PfP0 on asexual and sexual stages of P. falcipa-
rum has been documented recently (8). To determine whether
there may be surface localization of P0 domains on P. yoelii
merozoites, SIFA was performed using anti-PfP0 sera. Figure
2 shows double labeling of P. yoelii merozoites using the mono-
clonal antibody Mab302 and anti-PfP0N antibodies. Anti-
PfP0N antibodies and anti-MSP1 antibodies gave identical
staining patterns, with complete colocalization on every mer-
ozoite. Anti-PfP0C antibodies also showed the same results
(data not shown). These results show that the antibodies
against P. falciparum P0 protein do recognize the 35-kDa P.
yoelii P0 protein and that anti-PfP0 antibodies stain the surface
of P. yoelii merozoites.
Passive-transfer experiments. The titer of purified rabbit
anti-PfP0 IgG was determined by ELISA, by observing for
specific responses for PfP0N and PfP0C domains above the
GST activity. The titers of anti-PfP0N and anti-PfP0C IgG
were about 3,200 and .10,000, respectively. Antisera raised in
mice against PfP0 domains showed lower titers of 800 and
1,600 for anti-PfP0N and anti-PfP0C proteins, respectively
(data not shown).
Figure 3 shows the average parasitemia profile in the immu-
nized mice over the first 8 days. With injections on days 21, 0,
1, 3, and 5 and a challenge dose of 104 parasites, a significant
reduction in average parasitemia was observed. With extended
inoculations with anti-PfP0 IgG (Fig. 3II), it was observed that
the average parasitemia could be kept lower for slightly longer
periods. The parasitemia was kept low (,20%) in every mouse
over the first 7 days, while that in the control mice had reached
an average of 50%. On the average, anti-PfP0N was more
effective in restricting the parasitemia than anti-PfP0C. In each
of these experiments, mice injected with IgG prepared from
preimmune sera showed no significant difference in para-
sitemia compared to control mice (Fig. 3 and 4). Mice immu-
nized with IgG prepared from rabbit anti-GST sera also
showed no difference in parasitemia compared to mice receiv-
ing no IgG (data not shown). It has been documented earlier
that administration of anti-GST IgG has no effect on the
growth of the malarial parasite either in vitro or in vivo (16,
23).
Figure 4 shows the parasitemia profile of each mouse over a
period of 28 days for experiments I and II. All the control mice
(with parasites but no IgG injections) died by day 10, and the
profile was very similar for mice injected with preimmune IgG
(Fig. 5). With anti-PfP0 IgG, however, about 50% of the mice
cleared their parasites subsequently. In experiment I, three of
six mice, and in experiment II, two of six mice injected with
anti-PfP0N IgG controlled the parasitemia to ,2%, though
only two of these recovered completely (Fig. 5). Of the six mice
injected with anti-PfP0C IgG, three in each set cleared the
parasitemia and recovered completely (Fig. 5). The para-
sitemia varied in different mice but generally was more con-
trolled in mice treated with anti-PfP0N IgG (Fig. 4). In exper-
iment I, the highest average parasitemia was observed to be
28% on day 11 for mice injected with anti-PfP0N IgG, while
the highest average parasitemia was 53% on day 15 for anti-
PfP0C. In experiment II, these values were 48% on day 16 and
68% on day 12, respectively. In experiment II, where addi-
tional doses of IgG were injected, the initial parasitemia was
better controlled in every mouse (Fig. 4), and the survival
period for each mouse receiving anti-PfP0 IgG was increased
(Fig. 5).
A similar profile was obtained for passive-transfer experi-
ments (III) performed on mice with IgG prepared from mouse
sera (Fig. 6). As observed with IgG prepared from rabbit sera,
anti-PfP0N showed a greater reduction in average parasitemia
than anti-PfP0C IgG (Fig. 3 and 6). Virtually all the mice
injected with anti-PfP0N IgG kept the parasitemia in check
(,10% parasitemia) until day 5, while control mice had
reached .40% parasitemia (Fig. 6). All the control mice died
by day 8, but mice injected with anti-PfP0N IgG survived for 14
to 25 days (Fig. 5). The effect of anti-PfP0C IgG was weaker
than that of anti-PfP0N, but it did help in lengthening the
survival period in some of the mice (Fig. 5). The weaker effects
of anti-PfP0 IgG from mouse sera may be due to the lower
titers of mouse anti-PfP0 IgG.
DISCUSSION
We have recently reported the characterization of the ami-
no-terminal domain of the P. falciparum P0 ribosomal phos-
phoprotein PfP0N (16), which was isolated in a differential
immunoscreen using malaria-immune and patient sera (22).
Subsequent analysis showed that the PfP0C fusion protein also
reacted extensively with the immune serum samples and that
IgG from sera raised against both these domains inhibited the
growth of P. falciparum in vitro in a concentration-dependent
manner (8). The in vitro inhibition data showed that the block
occurs at the red cell invasion step (16). This indicated mero-
zoites as the target for anti-PfP0 IgG. The surface reactivity of
FIG. 2. IFA analysis of P. yoelii merozoites using double-staining technique.
Merozoites in two different fields are shown in the left and right panels. (A)
Mab302 culture supernatant, used directly and visualized with FITC-labeled
anti-mouse IgG. (B) Purified rabbit anti-PfP0N IgG solution, 1 mg/ml, used at a
1:50 dilution and visualized with rhodamine-labeled anti-rabbit IgG. Bar, 1 mm.
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both anti-PfP0N and anti-PfP0C antibodies on P. falciparum
merozoites, gametocytes, and gametes has been documented
recently (8). Neither the P0 gene nor the P0 protein has yet
been identified for the rodent malarial parasite P. yoelii. In this
paper, we have shown that anti-PfP0 antibodies raised against
P. falciparum P0 protein cross-react with the P. yoelii P0 pro-
tein and stain the surface of P. yoelii merozoites. The P0 pro-
tein has been shown to play diverse roles (14, 35, 36), and it is
likely that P0 plays a role in such diverse functions through
interactions with other protein complexes. In binding to ribo-
somes, P0 has been demonstrated to participate as a complex
in the membrane fractions of the endoplasmic reticulum (30).
The surface localization of P0 protein, which does not appear
to have consensus signal or transmembrane stretches, may
occur through interactions with other membrane proteins. In
this paper we also show that mice which received IgG purified
from sera raised against PfP0N and PfP0C polypeptides could
be protected against a challenge with the lethal strain 17XL of
P. yoelii. The control on the initial level of parasitemia and the
survival period of the mice were proportional to the titer and
frequency of anti-PfP0 IgG administered. These observations
indicate an important function(s) played by conserved P0 pro-
tein domains on the surface of the parasites, which presumably
constitute the target for anti-PfP0 IgG.
The in vivo protection of mice through the administration of
anti-PfP0 IgG can perhaps be divided into two main steps, the
initial delay in the rise of parasitemia followed by the ability of
the mice to resolve the infection. This is analogous to the
resolution of infections in mice injected with nonlethal strains
of P. yoelii. With a challenge of 106 parasites, mice infected
with the nonlethal 17X strain of P. yoelii can resolve the infec-
tion in about 16 to 26 days, depending on the inbred strain of
mice (20, 23). The parasitemia in such mice remains ,10% for
about 8 to 12 days before rising further. However, even with a
challenge of 104 parasites of the lethal strain 17XL, the para-
sitemia rises rapidly to levels .10% within 5 days of challenge
and continues to rise exponentially, resulting in the death of
mice within 10 days (23; this study). Passive immunization with
anti-PfP0 antibodies restrains the initial level of parasitemia in
the mice and appears to change the course of infection from
lethal to nonlethal. The ability of mice to finally resolve the
infection and recover completely depends on a large number of
genetic properties (17) as well as the individual constitutions of
the mice. Several passive immunizations have been performed
using anti-PfP0 IgG, and it was consistently observed that
anti-PfP0N IgG was more effective in restraining the initial
parasitemia. However, more mice recovered completely, de-
spite prolonged high parasitemia, among the mice injected
with anti-PfP0C IgG. The implications of this difference in the
effects of anti-PfP0N and anti-PfP0C are not clear, and the use
of clonal reagents against different domains of PfP0 may help
in the resolution of this observation.
Most of the Plasmodium peptide domains belonging to the
erythrocytic stages, which are currently considered protective,
confer protection mainly upon challenge with homologous
strains but have no effect on heterologous strains or species
(11, 23, 28). This is the first report of a cross-species passive
protection using antibodies raised against P. falciparum protein
protecting against challenges with P. yoelii. Passive immuniza-
tions have also been carried out using anti-PfP0 IgG against
FIG. 3. Average parasitemia as a function of time. Experiments I and II were performed with challenges of 104 and 3 3 104 P. yoelii 17XL parasites, respectively.
Mice were not immunized (F [passive control]) or were passively immunized with preimmune IgG (}), rabbit anti-PfP0N IgG (h), or rabbit anti-PfP0C IgG (). All
parasite challenges were made on day 0. The arrows indicate the IgG injection schedule. Large arrows, 0.6 mg/mouse (experiment I) and 1 mg/mouse (experiment II);
small arrows, 0.5 mg/mouse (experiments I and II).
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Plasmodium berghei parasite challenge, and a considerable in-
crease in the survival period of the immunized mice was ob-
served, once again indicating cross-species protection (Chat-
terjee et al., unpublished results).
Active vaccination studies with mice immunized with PfP0
domains yield results similar to passive immunizations (Sohoni
et al., unpublished results). Significant reductions in the initial
levels of parasitemia were recorded, and there was a consid-
erable lengthening of the survival period, but eventually all the
mice succumbed to the infection and died. P0 is a conserved
protein, and autoantibodies against the conserved carboxy-
terminal domain of the human P proteins have been detected
in 10 to 15% of patients with the autoimmune disorder sys-
temic lupus erythematosus (SLE) (13). It was therefore envis-
aged that vaccination attempts with large PfP0 constructs may
have the risk of generating activated B cells that may produce
host cross-reactive anti-P0 antibodies, whose role in lupus dis-
ease progression and pathology is controversial (24, 32, 33).
For vaccination studies, smaller stretches of P0 protein need to
be identified with no conformational homology to host P0
protein, to rule out possible long-term adverse effects. Passive
immunizations, on the other hand, have been performed ear-
lier on malaria patients with preparations of IgG obtained
from immune adults, and the recipients have shown no ill
effects from such treatments (10, 12, 25, 29). The sera of the
eight mice that recovered completely in our passive-transfer
experiments were tested for SLE parameters, such as reactivity
with anti-double-stranded or anti-single-stranded DNA and
antinuclear antibodies. No positive reactions were observed
(data not shown), indicating a lack of SLE-like symptoms.
It has been reported earlier that IgG from malaria-immune
adults, which conferred protection in malaria patients, did not
inhibit parasite growth on their own and did so only in the
presence of monocytes (4). However, the anti-PfP0 IgG was
found to inhibit the growth of P. falciparum independent of
monocytes (16). In studies using the merozoite surface protein
1 (MSP-1) of Plasmodium, it has been demonstrated that pro-
tection can be correlated with antigen-specific antibody titer
and not with CD41 T cells (19). Passive transfer of P. yoelii
hyperimmune sera resulted in resistance to a lethal challenge
of the parasite even in FcR gamma chain-deficient mice (27),
showing that protection is directly mediated by antibodies and
does not require the participation of Fc receptors. Thus, there
is evidence that IgG on its own may play important roles in
blocking crucial events in parasite biology. A comparison be-
tween in vitro and in vivo protection of neutralizing antibodies
in infection with vesicular stomatitis virus has been performed
(1). It was shown that in vitro the neutralizing activity corre-
lated with the measure of on rate, but in vivo the only deter-
minants for controlling the disease were a minimum avidity
FIG. 4. Parasitemia profile of each mouse in passive transfer experiments I
and II over a period of 28 days. Details of the experiments are given in the legend
to Fig. 3. Each symbol represents an individual mouse. Immunization: (a) none
(control) (CL); (b) preimmune IgG (PI); (c) rabbit anti-PfP0N IgG (a-P0N); (d)
rabbit anti-PfP0C IgG (a-P0C).
FIG. 5. Survival period of mice subjected to passive-transfer experiments.
Each dot represents the time point of the death of a mouse in that set. The
number of mice that recovered completely is shown next to the corresponding
treatment. See the legend to Fig. 3 for details.
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threshold and serum concentration of the neutralizing antibod-
ies. With these results, we establish the potential for the use of
specific anti-PfP0 IgG in therapeutic and prophylactic control
of malarial parasites. The therapeutic usage will be beneficial
in acute cases of cerebral malaria, especially in regions of
drug-resistant P. falciparum. P0 is a crucial protein, as estab-
lished by the knockout studies performed in S. cerevisiae (31)
as well as our in vitro growth inhibition assays in P. falciparum
culture (8, 16). It is therefore unlikely to undergo deletion or
a significant degree of polymorphism under therapeutic pres-
sure. The mapping of the important inhibitory B-cell epitopes
of PfP0 will help in the design of specific anti-PfP0 IgG as well
as in elucidation of the diverse functions of this multifunctional
protein.
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